

## Product datasheet for **TL314549V**

### AVPR V2 (AVPR2) Human shRNA Lentiviral Particle (Locus ID 554)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	AVPR V2 (AVPR2) Human shRNA Lentiviral Particle (Locus ID 554)
Locus ID:	554
Synonyms:	ADHR; DI1; DIR; DIR3; NDI; NDI1; V2R
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	AVPR2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_000054</a> , <a href="#">NM_001146151</a> , <a href="#">NR_027419</a> , <a href="#">NM_000054.1</a> , <a href="#">NM_000054.2</a> , <a href="#">NM_000054.3</a> , <a href="#">NM_000054.4</a> , <a href="#">NM_001146151.1</a> , <a href="#">BC101484</a> , <a href="#">BC101484.1</a> , <a href="#">BC015746</a> , <a href="#">BC033090</a> , <a href="#">BC041642</a> , <a href="#">BC080603</a> , <a href="#">BC112181</a> , <a href="#">NM_001146151.3</a> , <a href="#">NM_000054.6</a>
UniProt ID:	<a href="#">P30518</a>
Summary:	<p>This gene encodes the vasopressin receptor, type 2, also known as the V2 receptor, which belongs to the seven-transmembrane-domain G protein-coupled receptor (GPCR) superfamily, and couples to Gs thus stimulating adenylate cyclase. The subfamily that includes the V2 receptor, the V1a and V1b vasopressin receptors, the oxytocin receptor, and isotocin and mesotocin receptors in non-mammals, is well conserved, though several members signal via other G proteins. All bind similar cyclic nonapeptide hormones. The V2 receptor is expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, where its primary property is to respond to the pituitary hormone arginine vasopressin (AVP) by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of this gene is lost, the disease Nephrogenic Diabetes Insipidus (NDI) results. The V2 receptor is also expressed outside the kidney although its tissue localization is uncertain. When these 'extrarenal receptors' are stimulated by infusion of a V2 selective agonist (dDAVP), a variety of clotting factors are released into the bloodstream. The physiologic importance of this property is not known - its absence does not appear to be detrimental in NDI patients. The gene expression has also been described in fetal lung tissue and lung cancer associated with alternative splicing. [provided by RefSeq, Jul 2008]</p>



[View online »](#)

**shRNA Design:**

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact [techsupport@origene.com](mailto:techsupport@origene.com). If you need a special design or shRNA sequence, please utilize our [custom shRNA service](#).

**Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).